impact factor
logo
 

Small-vessel vasculitis

 

Rituximab in severe immunoglobulin-A vasculitis (Henoch-Schönlein) with aggressive nephritis


1, 2, 3, 4, 5, 6, 7, 8

 

  1. CMID-Nephrology and Dialysis Unit, Center of Research of Rheumatologic, Nephrologic and Rare Diseases, and Coordinating Centre of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital and University of Turin, Italy.
  2. CMID-Nephrology and Dialysis Unit, Center of Research of Rheumatologic, Nephrologic and Rare Diseases, and Coordinating Centre of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital and University of Turin, Italy.
  3. CMID-Nephrology and Dialysis Unit, Center of Research of Rheumatologic, Nephrologic and Rare Diseases, and Coordinating Centre of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital and University of Turin, Italy.
  4. CMID-Nephrology and Dialysis Unit, Center of Research of Rheumatologic, Nephrologic and Rare Diseases, and Coordinating Centre of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital and University of Turin, Italy.
  5. CMID-Nephrology and Dialysis Unit, Center of Research of Rheumatologic, Nephrologic and Rare Diseases, and Coordinating Centre of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital and University of Turin, Italy.
  6. CMID-Nephrology and Dialysis Unit, Center of Research of Rheumatologic, Nephrologic and Rare Diseases, and Coordinating Centre of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital and University of Turin, Italy.
  7. CMID-Nephrology and Dialysis Unit, Center of Research of Rheumatologic, Nephrologic and Rare Diseases, and Coordinating Centre of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital and University of Turin, Italy.
  8. CMID-Nephrology and Dialysis Unit, Center of Research of Rheumatologic, Nephrologic and Rare Diseases, and Coordinating Centre of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital and University of Turin, Italy. dario.roccatello@unito.it

CER13293
2020 Vol.38, N°2 ,Suppl.124
PI 0195, PF 0200
Small-vessel vasculitis

Free to view
(click on article PDF icon to read the article)

PMID: 32441647 [PubMed]

Received: 08/03/2020
Accepted : 16/04/2020
In Press: 22/05/2020
Published: 22/05/2020

Abstract

OBJECTIVES. Immunoglobulin-A vasculitis (IgAV) is a systemic small-vessel vasculitis in which renal involvement indicates severity of illness, and chronic kidney disease represents the most serious long-term complication. No treatment at present is specifically recommended for IgAV. Recently, rituximab (RTX) has been shown to be effective in case series of adults with IgAV. However, long term results are lacking. Aim of the study is to evaluate the effectiveness of RTX as induction therapy and maintenance of remission in adults with severe IgAV and aggressive glomerulonephritis.
METHODS:
This study included 12 adult-onset patients, 8 males and 4 females, mean age 45.1 years (range 19-75) with a mean follow-up duration of 33.7 months (range 6-144). All patients had a severe IgAV with biopsy proven crescentic nephritis. RTX was given for the treatment of a refractory disease or because of definite contraindications to standard therapies.
RESULTS:
Eleven patients (91.7%) achieved a clinical response at 6 months. Ten patients had a complete response (CR) while one had a partial response and was given an additional dose of RTX after 12 months for persistent proteinuria (1gr/24 hrs) despite systemic remission. He achieved a CR 6 months later. One patient was considered unresponsive to RTX and was switched to MMF. Among the 10 patients with CR, 1 needed maintenance doses of RTX every 6 months for iterative relapsing of severe purpura, 1 relapsed after 15 months and received a new induction course showing a CR again. A significant decrease in BVAS (p=0.031) and 24-hour-proteinuria (p=0.043) from RTX initiation through the last follow-up has been detected. One patient, who had a CR with RTX alone died after 6 months for therapy-unrelated cardiovascular cause.
CONCLUSIONS:
RTX proved to be effective and safe for induction and maintenance of long-lasting remission in severe IgAV with aggresive renal involvement. Data also suggest that RTX can be indicated not only for refractory cases, but can be also proposed as a first line therapy.

Rheumatology Article